IL1B and Venous thrombosis: The Canakinumab Antiinflammatory Thrombosis Outcome Study (CANTOS) trial demonstrated that inhibiting IL-1β pathway activation significantly reduced coronary artery disease morbidity and mortality in HIV uninfected persons [82].